Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Pavlos Msaouel

GU Oncology · MD Anderson Cancer Center

View

Dr. Karine Tawagi

GU Oncology · UIC

View

Dr. Talal Hilal

Lymphoma · Mayo Clinic College of Medicine

View

Dr. Midhun Malla

GI Oncology · UAB

View

Dr. Saad Usmani

Myeloma · MSK

View

Dr. Kamal Menghrajani

Leukemia · MGH

View

Dr. Hope Rugo

Breast Oncology · City of Hope

View

Dr. Gideon Dosunmu

GI Oncology · Emory Hospital Midtown

View

Dr. Virginia Borges

Breast Oncology · CU Anschutz Medical Campus

View

Dr. Naval Daver

Leukemia · MD Anderson Cancer Center

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    AKDr. Ali Khaki

    Dr. Ali Khaki

    Hematology & Oncology · Genitourinary Oncology
    Stanford Medicine
    ali

    Research

    Beyond the Point: Learning From Outcomes After Inpatient Immune Checkpoint Inhibitor Therapy.

    2025

    Via JCO Oncology Practice

    Research

    Response and Survival With Immune Checkpoint Inhibitor in Patients With Advanced Urothelial Carcinoma and Histology Subtypes.

    2025

    Via Clinical Genitourinary Cancer

    Research

    Cost-Effectiveness of Trimodal Therapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer.

    2025

    Via JAMA Network Open

    Research

    Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial.

    2025

    Via European Urology

    Research

    Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study.

    2025

    Via European Urology

    Research

    Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study.

    2025

    Via Cancer Medicine

    Research

    Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study.

    2025

    Via The Oncologist

    Research

    Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study.

    2025

    Via Urologic Oncology

    Research

    Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer.

    2024

    Via European Journal of Nuclear Medicine and Molecular Imaging

    Research

    An assessment of the direct and indirect costs of bladder cancer preceding and following a cystectomy: a real-world evidence study.

    2024

    Via Journal of Medical Economics

    Research

    Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor.

    2024

    Via Clinical Genitourinary Cancer

    Research

    Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data.

    2024

    Via European Urology Oncology

    Research

    Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma.

    2024

    Via Clinical Genitourinary Cancer

    Research

    Adjuvant checkpoint inhibitor trials: Is disease-free survival an appropriate endpoint?

    2023

    Via Journal of Cancer Policy

    Research

    Geriatric assessment in the older adult with genitourinary cancer: A narrative review.

    2023

    Via Frontiers in Oncology